Sarcopenia in COPD: relationship with COPD severity and prognosis

Abstract

Objective: To evaluate the prevalence of sarcopenia in COPD patients, as well as to determine whether sarcopenia correlates with the severity and prognosis of COPD. Methods: A cross-sectional study with COPD patients followed at the pulmonary outpatient clinic of our institution. The patients underwent dual-energy X-ray absorptiometry. The diagnosis of sarcopenia was made on the basis of the skeletal muscle index, defined as appendicular lean mass/height2 only for low-weight subjects and adjusted for fat mass in normal/overweight subjects. Disease severity (COPD stage) was evaluated with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria. The degree of obstruction and prognosis were determined by the Body mass index, airflow Obstruction, Dyspnea, and Exercise capacity (BODE) index. Results: We recruited 91 patients (50 females), with a mean age of 67.4 ± 8.7 years and a mean BMI of 25.8 ± 6.1 kg/m2. Sarcopenia was observed in 36 (39.6%) of the patients, with no differences related to gender, age, or smoking status. Sarcopenia was not associated with the GOLD stage or with FEV1 (used as an indicator of the degree of obstruction). The BMI, percentage of body fat, and total lean mass were lower in the patients with sarcopenia than in those without (p < 0.001). Sarcopenia was more prevalent among the patients in BODE quartile 3 or 4 than among those in BODE quartile 1 or 2 (p = 0.009). The multivariate analysis showed that the BODE quartile was significantly associated with sarcopenia, regardless of age, gender, smoking status, and GOLD stage. Conclusions: In COPD patients, sarcopenia appears to be associated with unfavorable changes in body composition and with a poor prognosis.

Relationship between pulmonary function and physical performance among community‐living people: results from Look‐up 7+ study

“…Previous studies described that reduced muscle function was correlated with decreased pulmonary function in subjects with lung disease, such as chronic obstructive pulmonary disease . Recently, Bahat et al .…”

Neglected areas on thorax computed tomography evaluation in patients with chronic obstructive pulmonary disease: Paravertebral muscles and para‐aortic adipose tissue

“…6 The principal limitation of this study is its retrospective nature. This may be attributed to local and systemic factors affecting compromised muscle tissue in the COPD patient group.…”

“…Acute phase reactants, particularly CRP, are released with an increase in IL-6. Costa et al 6 reported a prevalence of sarcopenia of 39.6% in COPD. Increased IL-6 and TNF-a are particularly associated with cachexia and skeletal muscle atrophy and dysfunction.…”

Frailty, Comorbidity, and COPD

“…In Brazil the prevalence of sarcopenia in COPD was 24% (34). Another study in Brazil using the Foundation of the National Institute of Health definition (FNIH) found a prevalence of sarcopenia in COPD was 12.4% (35). Patients with sarcopenia had a worse outcome.…”